Status:
COMPLETED
Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel
Lead Sponsor:
Institut Curie
Conditions:
Tumors
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate plasma alcohol concentration in patients receiving Paclitaxel or Docetaxel infusion.
Detailed Description
In this study, there is no experimental treatment, or experimental care.
Eligibility Criteria
Inclusion
- Chemotherapy with docetaxel or paclitaxel on an every 3-week schedule.
- Patient with bitherapy are eligible only if the taxane is the first infusion.
- All type of tumor.
- Age\>18 years old.
- Signed written informed consent.
Exclusion
- Patient under 18.
- Patient with bitherapy, if docetaxel or paclitaxel is not administered first.
- Patient deprived of liberty.
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01448759
Start Date
October 1 2011
End Date
February 1 2012
Last Update
April 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Curie
Paris, France, 75005